Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus
NCT07913919Recruiting
- Sponsor
- University of Cambridge
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by University of Cambridge. Primary endpoint: Coronary artery 68Ga-DOTATATE maximum tissue-to-blood ratio at 16 weeks. Started Nov 2025; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07913919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913919.